Analyst Price Target is $273.63
▲ +13.46% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Becton, Dickinson and in the last 3 months. The average price target is $273.63, with a high forecast of $297.00 and a low forecast of $250.00. The average price target represents a 13.46% upside from the last price of $241.16.
Current Consensus is
The current consensus among 9 polled investment analysts is to hold stock in Becton, Dickinson and. This rating has held steady since June 2021, when it changed from a Buy consensus rating.
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens; and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.